3-4 October 2016, La Jolla, San Diego, USA

www.globalengage.co.uk/microbiome.html www.globalengage.co.ukprobiotics-usa.html

4th Microbiome R&D and Business Collaboration

Forum: USA COLLABORATIONS IN MICROBIOTA RESEARCH, LIVE

BACTERIAL THERAPEUTICS, HUMAN HEALTH & DISEASE

&

Probiotics Congress: USA

RESEARCH, DEVELOPMENT & APPLICATION OF PROBIOTICS AND

PREBIOTICS IN HUMAN AND ANIMAL HEALTH

As part of its international microbiome series, Global Engage is pleased to announce the co-located 4th Microbiome R&D and Business Collaboration

Forum: USA and Probiotics Congress: USA which will be held on 3-4 October 2016 at the San Diego Marriott La Jolla.

Recent research has demonstrated the importance of our microbes in our maintaining health and their possible use in treating and preventing

disease. As microbial dysbiosis has been shown to be linked to several long-term diseases; approaches that modify our microbiome by adding or

removing individual microbes or entire microbial communities have been shown to have a significant impact on the health of an individual. The

potential to use the microbiome as a therapy and to design treatments customised to the patient’s microbiome has created a rapidly growing

interest from the pharmaceutical industry and investors and it looks set to continue to grow in the coming years with the emerging microbiome

market expected to reach US$658 million by 2023. This excitement has been typified by the launch, at the White House, of the National Microbiome

Initiative. There is a rich source of information, backing and partnering opportunities for researchers and companies looking for opportunities in this

field as well as the burgeoning probiotic space.

Attracting over 350 attendees, the 9th meeting in the global series will build upon the success of last year’s meeting which attracted over 200

attendees as well as our highly popular European and Asia forums to explore the interface between our evolving cultures, technologies and our

microbiome through a series of interactive presentations with leading academics and industry experts, panel discussions and an exhibition area

allowing solution providers to showcase their products and services. The Global Engage series is rapidly gaining a fantastic reputation for fostering

partnerships across academia, pharma and biotech. If looking to either learn more from the top scientists in the microbiome and probiotic space;

showcase exciting developments in your research; or seek partnerships and funding within the industry; it is a congress not to be missed.

Conference Synopsis

Gut Microbiota in Health and Disease Connections to IBD and IBS & Gut microbiota transplantation

Innate immune system and host-pathogen Interaction

Associations of obesity and metabolic disease

Microbiomes to Medicines

Industry-academic research platforms

Role of synthetic biology

Sequencing and bioinformatics of the human microbiome

Research into the microbiome an HIV

Microbiome in cancer

Case studies: industry success stories and establishment of microbiome

centers

Skin Microbiota Diversity of skin communities

Panel: Developing skin microbiota-mediated therapeutic approaches

Mechanisms of Tolerance

Fungal Microbiome in Skin Health

Probiotic approaches to treat skin disorders

Skin and scalp microbiomes

Case studies and therapeutic potential in acne, eczema, atopic

dermatitis, and microbiomes of chronic and acute wounds

R&D Outside the Gut Lung microbiota – COPD, HIV, and airway diseases

New therapeutic possibilities for lung disease

Microbiome of the female urogenital tract and pregnancy

Gut-brain axis

Oral microbiome therapeutics

Commercialisation of the Microbiome Panel discussion: Venture capital and microbiome

investment

Panel discussion: Pharma and the microbiome

Crowd funding and other fundraising options

What makes commercial sense from both the pharma and

patient perspective?

Necessary QC and regulatory approaches

Securing investment (extended networking sessions outside

the congress program)

Development, application & acquisition of technology

platforms within the microbiome space

Beyond the noise – opportunities and overhype

Contemplating novel antibiotic therapies that do not

destroy the healthy microbiome

Bringing live microbial products to market – IP, regulation,

GMP

Probiotics Congress Probiotics and digestive health

Prebiotics and functional foods

Probiotics in pediatrics

Role of human milk oligosaccharides

Regulation and product development

Strain identification, designation and safety

Probiotics and prebiotics for animal health

Pro- and prebiotics and dietary interactions

Panel: QA and verification of dietary supplement products

Confirmed Speakers and Chairs

Rob Knight

Professor of Pediatrics and

Computer Science & Engineering,

University of California, San Diego

Tiffany Scharschmidt

Assistant Professor of

Dermatology, University of

California, San Francisco

David Nicholson

Executive Vice President, Brands

R&D, Allergan

Beth McCormick

Professor & Executive Director,

Center for Microbiome Research,

University of Massachusetts

Richard Gallo

Professor and Interim Chair,

Department of Dermatology,

University of California, San Diego

Anuk Das

Head of Scientific Innovation,

Janssen Human Microbiome

Institute

Marc Güell

Chief Scientific Officer,

S-Biomedic

Thomas L. Dawson, Jr.

Senior Principal Investigator,

Agency for Science, Technology,

and Research (A*STAR), Institute

of Medical Biology (IMB),

Singapore

Ying-Chieh Tsai

Professor, National Yang Ming

University, Taiwan

Alison Morris

Professor of Medicine and

Immunology, University of

Pittsburgh

John Zibert

Chief Medical Officer, Medical

Director, LEO Innovation Lab,

Denmark

Aaron Del Duca

Vice President, Technology, DNA

Genotek

Greg Leyer

Chief Scientific Officer, UAS

Laboratories

Mark Morrison

Professor & Chair, Microbial

Biology and Metagenomics,

University of Queensland

Diamantina Institute, Australia

Clotilde Teiling

Sr. Marketing Programs Manager,

Microbial Genomics and Infectious

Disease, Illumina Inc.

Craig Murphy

Senior Director of Immunology &

Therapeutic Innovation, Ferring

Pharmaceuticals

Inga Peter

Associate Professor, Department

of Genetics and Genomic

Sciences, Icahn School of

Medicine at Mount Sinai

Ma Somsouk

Associate Professor of Medicine,

Division of Gastroenterology,

University of California, San

Francisco

Arpita Maiti

Director, External R&D Innovation,

Inflammation and Immunology,

Pfizer

Eva Berkes

Co-Founder & Chief Scientific

Officer, Quorum Innovations

Harro Timmerman

Principal Scientist Microbiota in

Health & Disease, NIZO Food

Research BV, The Netherlands

Michael Step

Chief Executive Officer,

Ritter Pharmaceuticals

Maxence Desjonquères

Chief Executive Officer,

Biose

Ming Wang

CEO, Phanes Therapeutics

[SESSION CHAIR]

Işil Tüzün Weber

Process Engineer Technical

Operations Manufacturing, SynCo

Bio Partners

Bruce McConnell

Head of Business Development,

Glycom A/S

Elizabeth Hohmann

Associate Professor of Medicine,

Massachusetts General Hospital

Avi Spier

Director, Strategic Alliances, Novartis

Institutes for Biomedical Research,

Novartis

Brian Varnum

Chief Development Officer, C3 Jian

Inc

Bernat Olle

Co-founder & Chief Operating

Officer, Vedanta Biosciences, Inc. /

Vice President, PureTech

Chase Beisel

Assistant Professor, Department of

Chemical & Biomolecular

Engineering, North Carolina State

University

Dana Hosseini

CEO and Co-Founder, ProdermIQ

Leopoldo Segal

Assistant Professor, Department of

Medicine, New York University

School of Medicine

Robert Osgood

Associate Professor of Microbiology,

Rochester Institute of Technology

Jane Foster

Associate Professor, Department of

Psychiatry & Behavioural

Neurosciences, McMaster University,

Canada

Lada Rasochova

Chief Executive Officer,

Dermala Inc.

Nick Conley

Chief Executive Officer,

EpiBiome

Pierre Belichard

CEO, Enterome

Henrik Bjørn Nielsen

Chief Scientific Officer, Clinical-

Microbiomics

4th Microbiome R&D and Business Collaboration Forum & Probiotics Congress

3-4 October 2016 – La Jolla, San Diego

Confirmed Speakers and Chairs continued…

Sean Davies

Associate Professor of

Pharmacology, Vanderbilt

University

Gregory J. Kuehn

President and COO, Metabiomics

Nadir Mahmood

Director, External Alliances,

Second Genome

Duncan Peyton

CEO, 4D pharma plc.

Lynne V. McFarland

Research Scientist, VA Puget

Sound Healthcare System/

Affiliate Associate Professor, U.

Washington

Jens Noesgaard Jørgensen

Global Product Manager, Swine /

Animal Health & Nutrition, Chr.

Hansen

Louise Vigsnæs

Preclinical Development

Manager, Glycom A/S, Denmark

Johan van Hylckama Vlieg

Vice President Microbiome &

Human Health Innovation,,Chr.

Hansen A/S, Denmark

Moul Dey

Associate Professor, South Dakota

State University

[SESSION CHAIR]

Julian Trachsel

PhD Student, USDA-ARS

Keith Garleb

Director R&D Programs, Abbott

Nutrition R&D

John Hale

Research and Development

Manager, BLIS Technologies, New

Zealand

Seong Jae Yoo

Scientific Liaison, United States

Pharmacopeia (USP)

David J. Kyle

CEO, Evolve Biosystems

Isaac Bright

Vice President, Corporate

Development, Synthetic Biologics,

Inc.

Lindsay Peed

Lead Scientist Life Sciences,

Microbiology, Kimberly-Clark

Larry Weiss

Chief Medical Officer, AOBiome

Lars Bode

Associate Professor, University of

California, San Diego

Anders Daniel Andersen

Senior Scientific Advisor, LEO

Innovation Lab, Denmark

Jiangchao Zhao

Assistant Professor, University of

Arkansas

Marion Leclerc

Team Leader, MICALIS, INRA,

France

Susan Cho

President, Nutrasource, Inc

Pieter Van den Abbeele

Contract Research and

Technology Director, ProDigest

Frank Schuren

Senior Scientist Microbiology,

TNO

Lee Jones

Founder, President & CEO,

Rebiotix

Elsbeth Pekelharing

Science Liaison, Winclove

Probiotics

Malcolm Kendall

Co-Founder & CEO, Microbiome

Insights, Inc.

Eric de la Fortelle

Venture Partner, Seventure Partners

Maria Marco

Associate Professor, University of

California, Davis

Anurag Pande

Vice President, Scientific Affairs,

Sabinsa Corporation

Pradeep Dudeja

Professor of Physiology, Division of

Gastroenterology & Hepatology,

University of Illinois, Chicago, USA

Buffy Stahl

Genomics and Microbiome Science

Leader, DuPont Nutrition & Health

Michael Gänzle

Professor, Department of

Agricultural, Food & Nutritional

Science, University of Alberta,

Canada

Ravi Kumar

Scientist II, Novozymes Inc

Jan Suchodolski

Associate Professor, Department of

Small Animal Clinical Sciences,

Texas A&M University

Brad Saville

Chief Scientific Officer/EVP &

Founder, Prenexus Health

Dario Gutierrez

Immuno-Biology Lead, Merck

Research Laboratories

4th Microbiome R&D and Business Collaboration Forum & Probiotics Congress

3-4 October 2016 – La Jolla, San Diego

Platinum Sponsors

Gold Sponsors

Silver Sponsors

Sponsors

1

4th Microbiome R&D and Business Collaboration Forum & Probiotics Congress

3-4 October 2016 – La Jolla, San Diego

8.00-8.50am Registration & Coffee [La Jolla Ballroom Salon E-H]

8.50am- 9.00am

Global Engage Welcome Address & Morning Chair’s Opening Remarks [La Jolla Ballroom Salon A-D] Stream Chair: Nadir Mahmood, Director, External Alliances, Second Genome

Global Engage Welcome Address & Morning Chair’s Opening Remarks [Soledad Ballroom] Stream Chair: Pradeep Dudeja, Professor of Physiology, Division of Gastroenterology &

Hepatology, University of Illinois, Chicago

9.00am- 9.35am

Keynote Address: Is There a Culture Gap in Translating Microbiomes to Medicine? Over the last decade, research of the “human microbiome” has gained prominence in terms of the scale of investment, professional and media reportage, and social interest in its findings. Its emergence as a distinct field of research has been both a cause, and a consequence of the rapid advances in DNA/RNA sequencing technologies and computational methods of data analysis. Importantly, these approaches have expanded our understanding of the relevance of the human microbiota beyond the realms of pathogenesis and infectious disease to include an appreciation of the role for “commensal” microbes to a person’s “wellness”; as well as the host’s susceptibility, resilience and relapse to both chronic and acute diseases. However, and despite the advances via microbiome research, much remains obscure in terms of defining when variations in the microbiota are the cause, or a consequence of host phenotype, which constrains the translation of this phenomenology into social impact. This presentation will summarise some of our efforts to extend human microbiome research beyond its genomics roots, to take advantage of other principles inherent to environmental microbiology.

CONFIRMED: Mark Morrison, Professor & Chair, Microbial Biology and Metagenomics, University of Queensland Diamantina Institute, Australia

Keynote Address: Interplay between Diet and Intestinal Lactobacillus Host diet has a significant influence on the composition of the indigenous intestinal microbiota. Less understood is the importance of diet on probiotic performance. Our pre-clinical studies have shown that foods high in refined sugar and fat result in significant reductions to indigenous Lactobacillus species populations yet promote the survival and efficacy of ingested, probiotic Lactobacillus in a compensatory manner, providing evidence that probiotics have pivotal roles in the maintenance and restoration of the intestinal ecosystem when obesogenic diets are consumed. This distinction is also supported by the capacity of probiotic Lactobacillus to prevent excessive weight gain and glucose intolerance.

CONFIRMED: Maria Marco, Associate Professor, University of California, Davis

9.35am- 10.05am

The Center for Translational Microbiome Research (CTMR): An Open Academic Research Collaboration between Ferring Pharmaceuticals and the Karolinska Institute

Our overriding goal is to better understand the contribution of the human microbiome to the physiology and pathophysiology of disease, thereby opening opportunities for development of novel therapies to improve people’s lives. We go into the space with the view that it is important to sort out the hope from the hype. It is our view that the only way to achieve this is to know what is ‘normal’.

Currently there exist many small pilot studies with poor epidemiological design and observations reported need to be confirmed in larger well-designed (and preferably) population-based studies with long follow-up periods

Our initial efforts include the Karolinska’s prospective population-based studies in the gastroenterology field; however, we are planning studies in reproductive health and women’s health areas.

CONFIRMED: Craig Murphy, Senior Director of Immunology & Therapeutic Innovation, Ferring Pharmaceuticals

Developing the Next Generations of Bacteria for Probiotic and Therapeutic Applications

CONFIRMED: Johan van Hylckama Vlieg, Vice President Microbiome & Human Health Innovation, Chr. Hansen A/S, Denmark

10.05am- 10.35am

Sponsored Presentation: EB8018- a novel FimH Blocker for the treatment of Crohn’s & NEC Modulation of the Dysbiotic Microbiome by FimH Blockers in IBD:

Gammaproteobacteria (Adherent Invasive E Coli, Shigella, Klebsiella) are opportunistic pathobionts present under certain conditions in the compromised gut microbiome of Inflammatory Bowel Disease patients (Crohn’s Disease, Necrotizing Enterocolitis, Irritable Bowel Syndrome, etc...). It is a key causative factor of intestinal inflammation and immune hyper-responsiveness in IBD

FimH adhesin is the main virulence factor shared within the Gammaproteobacteria family

Blocking the FimH adhesion represents a novel therapeutic approach in treating dysbiosis associated with IBD – alternative to existing drugs incl. antibiotics

EB8018 is a novel non-steroid, non-immunomodulatory, non-biological approach to treat Crohn’s Disease with highly potent anti-adhesive activity

CONFIRMED: Pierre Belichard, CEO, Enterome Bioscience

Sponsored Presentation: Shedding light on Prebiotics: Their Role in Human Health

Differences between prebiotics

The impact of structure - C5 versus C6

Different roles of soluble and insoluble components

Synergies with probiotics

CONFIRMED: Brad Saville, Chief Scientific Officer/EVP & Founder, Prenexus Health

10.35am-11.45am

Morning Refreshments [La Jolla Ballroom Salon E-H] Even Numbered Poster Presentations & Scheduled One-to-One Meetings

Agenda: Day One – Monday, 3 October 2016

Gut Microbiota in Health and Disease [La Jolla Ballroom Salon A-D]

Session Chair: Avi Spier, Director, Strategic Alliances, Novartis Institutes for Biomedical Research, Novartis

Skin Microbiota [ Irvine, Newport ]

Session Chair: Lada Rasochova, CEO, Dermala Inc.

Probiotics Congress [Soledad Ballroom] Stream Chair: Pradeep Dudeja, Professor of Physiology,

Division of Gastroenterology & Hepatology, University of Illinois, Chicago

11.45am-12.10pm

Frozen, Encapsulated Fecal Microbiota Transplant for C. difficile Infection Fecal Microbiota Transplantation (FMT) is an accepted treatment for recurrent C. difficile infection (CDI). We have prospectively followed 200 patients treated with FMT capsules at Massachusetts General Hospital. Patients 7-95 years of age, with 3 or more mild-to-moderate episodes of CDI, or 2 episodes requiring hospitalization, were treated with open label capsule FMT (15 capsules on each of 2 successive days). Cure (defined as resolution of diarrhea, or no recurrence of diarrhea within 8 weeks) was achieved in 82% with a single dose of 30 capsules, rising to 92% with a second dose in those who relapsed based upon worsening symptoms and fecal testing. Adverse events were minor, with the exception of two patients diagnosed by biopsy with ulcerative colitis (UC) in the follow-up period. In one subject UC was clinically suspected before FMT, in the other not. FMT by capsule is offered as standard care for CDI at our institution.

CONFIRMED: Elizabeth Hohmann, Associate Professor of Medicine, Massachusetts General Hospital

Identification and Therapeutic Application of Rationally Selected, Novel Components of the Human Skin Microbiome The skin protects us from microbial invasion and is essential for development of a normal immune system. Antimicrobial peptides (AMPs) are necessary for epithelial function and participate in the pathogenesis of common human diseases such as atopic dermatitis. To test if the microbiome contributes to the function of human skin we developed a high-throughput screening system for AMP function from human skin bacteria. A library of strains was assembled, and several previously unknown bacterial products were identified with potent antimicrobial activity. Subsequent animal and human clinical trials have confirmed that these molecules are safe and act on the skin to inhibit S. aureus colonization while maintaining the normal flora. This rational microbiome functional profiling approach has defined specific molecules enabling bacteriotherapy of human disease.

CONFIRMED: Richard Gallo, Professor and Interim Chair, Department of Dermatology, University of California, San Diego

Probiotics for the Prevention of Pediatric and Adult AAD: Making the Right Choice A total of 26 RCTs for pediatric AAD and 44 RCTs for adult AAD were included. The pooled RR for pediatric and adult AAD indicated probiotics, in general, were significantly effective, but due to strain-specific efficacy sub-group analyses were required. Of the 17 different types of probiotics tested in children, only three were significantly effective and 14 lacked confirmatory RCTs. For the 23 different types of probiotics tested in adults, 6 were significantly effective, while 4 types were not effective and 13 lacked confirmatory RCTs.

CONFIRMED: Lynne V. McFarland, Research Scientist, VA Puget Sound Healthcare System/ Affiliate Associate Professor, U. Washington

12.10pm-12.35pm

Delivery of Programmable Nucleases for Rationally Altering Microbial Communities The human microbiome comprises thousands of bacterial strains and species, where we still know little how individual members contribute to community function and human health. In this talk, I will highlight my research group's ongoing work on developing targeted programmable antimicrobials to remove individual members of a microbial community. These antimicrobials are based on CRISPR-Cas systems immune systems that have gained widespread attention for genome editing but also hold potential as next-generation antimicrobials. I will discuss our efforts to develop generalized delivery vehicles that rely on engineered bacteriophages and how these vehicles can be exploited to delivery CRISPR antimicrobials to multiple species. By removing individual members of a microbial community, we seek to evaluate the specific role of that member in microbiome function and begin rationally altering the composition of the human microbiome in order to improve human health.

CONFIRMED: Chase Beisel, Assistant Professor, Department of Chemical & Biomolecular Engineering, North Carolina State University

Elucidating Mechanisms of Tolerance to Commensal Skin Microbes Our skin contains billions of lymphocytes that protect us from infection by recognizing and responding to microbial antigens. Yet, healthy skin shows no evidence of destructive inflammation directed against commensal bacteria. Using an in vivo model to study the commensal-specific CD4+ T cell response, we recently observed that immune tolerance to skin commensals is preferentially established early in life and mediated by a unique population of regulatory T cells in neonatal skin. In fact, commensals themselves help facilitate immune tolerance by augmenting accumulation of these Tregs. Further efforts to dissect the cellular and molecular mechanisms that mediate adaptive immune tolerance to skin commensals may open new therapeutic opportunities for inflammatory skin disease.

CONFIRMED: Tiffany Scharschmidt, Assistant Professor of Dermatology, University of California, San Francisco

Use of Probiotic Lactobacillus reuteri for control of enterotoxigenic Escherichia coli Enterotoxigenic Escherichia coli cause diarrhea in infants, piglets, and calves. Probiotic Lactobacillus reuteri provided as freeze dried preparation, or ingested as part of fermented food or feed reduces intestinal colonization by ETEC and thus may prevent diarrhea or reduce the severity of the disease. Specific metabolic traits of L. reuteri, particularly the formation of reutericyclin or exopolysaccharides, specifically contribute to probiotic properties of this organism.

CONFIRMED: Michael Gänzle, Professor, Department of Agricultural, Food & Nutritional Science, University of Alberta, Canada

12.35pm- 1.00pm

Reconstituting the Gut Microbiome: Lessons from HIV Infection

Dysbiosis is frequent in the setting of HIV, and like C. difficile, can be stably altered

Dysbiosis in the setting of HIV is associated with systemic markers of inflammation

Interventions to reconstitute the microbiome during HIV will inform other disease conditions

CONFIRMED: Ma Somsouk, Associate Professor of Medicine, Division of Gastroenterology, University of California, San Francisco

Microbiome: Cause or Consequence of Inflammatory Skin Diseases? The skin and gut microbiome in patients with chronic skin diseases such as psoriasis and atopic dermatitis (eczema) is affected by the diseases. If the change in diversity is a cause or consequence of the diseases is an open question. The talk will include preliminary data on the microbiome in patients with psoriasis obtained on the skin, gut and mouth, and relating to in particular the bacteria Coprococcus species, Akkermansia, Ruminococcus, and Pseudobutyrivibrio previously found in the gut flora in patients with psoriasis. For atopic dermatitis the potential in introducing microbes that control staphylococcus aureus predominance or a general reduction of skin microbes, which may be followed by a prompt recolonization with a community of broader diversity will be discussed.

CONFIRMED: John Zibert, Chief Medical Officer, Medical Director, LEO Innovation Lab, Denmark

Towards New Probiotics in Crohn's disease We monitored Crohn's disease patients before, during, 6 and 12 months after surgery. The probiotic strain some ingested did not have any impact on the outcome of the surgery. Conversely, by using a network analysis of the biopsies’ microbiota, we found a set of species that could be a potential new probiotic mix in adult after surgery. We then analyzed some of the cultured species in axenic rodent models.

At 6 months after surgery, individuals harboring a set of species within their control biopsies will be in remission at 12 months. The other ones will be in relapse. (Mondot et al, Gut 2016)

From a biopsy the outcome of the surgery could be predicted and patient care could be modified accordingly

These species are organized as a network of abundance

In animal models some of these species produced beneficial metabolites

CONFIRMED: Marion Leclerc, Team Leader, MICALIS, INRA, France

1.00pm -1.15pm

Company Showcase: Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Prevention

Metabiomics MB-01 Colorectal Adenoma Microbiome Clinical Research Study, Breakthrough Protocols and Predictive Modeling Workflow

Metabiomics MB-01 MultiTag NGS 16S rRNA Sequencing Technology

Metabiomics Microbiome Diagnostics Platform and Pipeline

CONFIRMED: Gregory J. Kuehn, President and COO, Metabiomics

No Presentation in this stream

Company Showcase: An Advanced in vitro Technology Platform to Study the Mechanism of Action of Pre- and Probiotics in the Gastrointestinal Tract

The Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) is a unique technology platform to produce data complementary to in vivo studies to potentially understand the mechanism of action of actives in the GI tract

The full physiology and microbiology of the human and animal GI tract can be simulated making use of a computer-controlled device which reproduces stomach, small intestine and the different areas of the colon. The device can be coupled to cell lines and biopsies to further investigate the impact on the host.

Potential endpoints: where a fiber is fermented and with which effect? Can a probiotic survive the passage in the upper GI tract? Which is the best formulation? Can a probiotic adhere to the gut wall? Can a pre/probiotic modulate the metabolism and composition of the gut microbiota? And what about gut permeability (i.e. leaky gut)?

CONFIRMED: Pieter Van den Abbeele, Contract Research and Technology Director, ProDigest

1.15pm-2.15pm

Lunch [La Jolla Ballroom Salon E-H]

[La Jolla Ballroom Salon A-D] Session Chair: Ming Wang, CEO, Phanes Therapeutics

[ Irvine, Newport ] Session Chair: Lada Rasochova, CEO, Dermala Inc.

[Soledad Ballroom] Session Chair: Susan Cho, President, Nutrasource, Inc.

2.15pm -2.45pm

Sponsored Presentation: Mining the Microbiome for the Next Generation of Therapeutics There is increasing evidence that the gut microbiome modulates human physiology for health and disease. This intricate relationship involves interaction of bacterial bioactive molecules with host mechanisms to promote disease pathophysiology. Second Genome has built a drug discovery platform that can identify, express and screen microbiome bioactives. We have deployed these capabilities to identify bacterial proteins that improve intestinal barrier integrity, reduce inflammation and modulate glucose and insulin sensitivity.

CONFIRMED: Nadir Mahmood, Director, External Alliances, Second Genome

A Forbidden Kingdom: The Fungal Microbiome in Skin Health. Why it’s Important, What Needs To Be Done, and How to Intervene In the scope of human microbiome research, there remain two related and unexploited areas, skin and fungi. As an example of the importance and opportunity in leveraging the skin mycobiome, this presentation will review current understanding of healthy versus diseased scalp, the scalp Mycobiome, the role of Malassezia in dandruff and seborrheic dermatitis, the state of the art in Malassezia genomics, and how current treatment options influence the scalp Mycobiome. We identified candidate organisms, defined pathogenic mechanisms, and designed successful treatment interventions for the consumer market. These strategies may also be broadly applied across skin health.

CONFIRMED: Thomas L. Dawson, Jr., Senior Principal Investigator, Agency for Science, Technology, and Research (A*STAR), Institute of Medical Biology (IMB), Singapore

Mechanisms Underlying Anti-Diarrheal Effects of L. acidophilus in a Model of Infectious Diarrhea and Colitis Impaired absorption of electrolytes is a hallmark of diarrhea associated with inflammation or enteric infections. Intestinal epithelial luminal membrane NHE3 (Na+/H+ exchanger 3) and DRA (Cl-/HCO3- exchanger) play key roles in mediating electroneutral NaCl absorption. Our previous studies showed that the probiotic Lactobacillus acidophilus (LA) increased DRA and NHE3 function and expression and conferred protective effects in experimental colitis. Current studies were aimed at evaluating the efficacy of LA in counteracting NHE3 and DRA inhibition in C rodentium infection. FVBN mice challenged with C. rodentium with or without administration of live LA were assessed for NHE3 and DRA expression and diarrheal phenotype, myeloperoxidase (MPO) activity and proinflammatory cytokines. LA counteracted C. rodentium-induced inhibition of colonic DRA and NHE3, attenuated diarrheal phenotype and MPO activity. Further, LA blocked C. rodentium induction of cytokines. In conclusion, we provide mechanism of anti-diarrheal effects of LA in a model of infectious diarrhea and colitis.

CONFIRMED: Pradeep Dudeja, Professor of Physiology, Division of Gastroenterology & Hepatology, University of Illinois, Chicago

2.45pm -3.15pm

How NGS is Revolutionizing Microbiology

CONFIRMED: Clotilde Teiling, Sr. Marketing Programs Manager, Microbial Genomics and Infectious Disease, Illumina Inc.

Panel Discussion: Skin Microbiota Therapeutics

Landscape of the skin microbiome

Skin microbiota and probiotics

Establishing skin microbiome biotechs and treatments

CONFIRMED:

Chair: Dana Hosseini, Chief Executive Officer & Co-Founder, ProdermIQ

Marc Güell, Chief Scientific Officer, S-Biomedic

Eva Berkes, Co-Founder & Chief Scientific Officer, Quorum Innovations

Lada Rasochova, CEO, Dermala Inc.

Sponsored Presentation: Probiotic LRC™: An Evidence-based Approach to Supporting Heart Health Studies have shown that alterations to the gut microbiome affect levels of bile acid metabolism and that a dysbiotic microbiome may be associated with metabolic disease. A disrupted gut microbiome, including a reduction of bile salt hydrolase active bacteria, can significantly impair the metabolism of bile acids and may result in disrupted cholesterol and glucose homeostasis. Currently, there is significant potential for developing probiotic treatments that impact bile acid metabolism in concert with the microbiome field. Our group has demonstrated that supplementing the human gut with bile salt hydrolase active LRC™ can bring about significant improvements in lipid profile and markers of inflammation. Here we will present the development of this unique probiotic, results of randomized controlled trials and expectations going forward.

CONFIRMED: Greg Leyer, Chief Scientific Officer, UAS Laboratories

3.15pm -3.40pm

Targeting the Microbiome to Promote Health Through advances in science, we have a better understanding of the role the microbiome plays in wellness and disease. We have learned that balance and imbalance in the microbiota can be assessed and linked to diseases with unmet patient needs, like cancer, inflammatory bowel disease and diabetes. The Janssen Human Microbiome Institute, created in 2015, is committed to finding new solutions or interventions targeting the microbiome that can promote health. By building their internal expertise and developing an open innovation approach they aim to work with scientific and entrepreneurial collaborators around the world across academia, government and the life science industry who share their passion.

CONFIRMED: Anuk Das, Head of Scientific Innovation, Janssen Human Microbiome Institute

Ammonia Oxidizing Bacteria - A Live Topical Therapeutic AOBiome is exploring the role of Nitrosomonas Eutropha, an Ammonia Oxidizing Bacteria (AOB) as an ancestral human skin commensal and a bio-therapeutic. AOBiome is currently in Phase 2 clinical trials with the first live topical therapeutic and for the prevention and treatment of inflammatory disorders of the skin including acne, eczema, and rosacea. The company has released a cosmetic formulation of the bacteria under the brand name Mother Dirt. Topics covered will include:

Discovery of AOB as skin keystone commensals

Biology of Nitrosomonas Eutropha

Clinical Development of AOB as a dermatologic therapeutic

Consumer Products as a tool in therapeutic development

CONFIRMED: Larry Weiss, Chief Medical Officer, AOBiome

No Presentation in this stream

3.40pm -4.30pm

Afternoon Refreshments [La Jolla Ballroom Salon E-H] Odd Numbered Poster Presentations & Scheduled One-to-One Meetings

4.30pm -5.00pm

Panel Discussion: Development of Microbiome Therapeutics

Microbiota as therapeutics

Breaking through the noise

Review of where pharma is at with the microbiome

Areas of focus and future development

How have things moved on in the last year?

Probiotics and Psoriasis - an Inflammatory Skin Condition. What’s the Potential?

The gut microbiota is important for host health, and gut bacterial dysbioses are associated with gastrointestinal inflammatory conditions in both pediatric and adult populations.

Through immunomodulatory actions, certain probiotic strains are thought to be able to influence both the mucosal and the systemic immunity, which may extend also to inflammatory conditions in the skin.

Psoriasis is a chronic skin inflammatory condition that affects approximately 2% of the population. Some of these are further burdened by gut-related comorbidities, such as inflammatory bowel diseases. Some research suggest that certain immune mediators are involved in both the skin manifestations and in the mucosal inflammation, which highlights a therapeutic potential for gut

targeted interventions that may be helpful for psoriasis patients.

CONFIRMED: Anders Daniel Andersen, Senior Scientific Advisor, LEO Innovation Lab, Denmark

5.00pm -5.30pm

CONFIRMED:

Chair: Avi Spier, Director, Strategic Alliances, Novartis Institutes for BioMedical Research

David Nicholson, Executive Vice President Brands R&D, Allergan

Arpita Maiti, Director, External R&D Innovation, Inflammation and Immunology, Pfizer

Craig Murphy, Senior Director of Immunology & Therapeutic Innovation, Ferring Pharmaceuticals

Lee Jones, Founder, President & CEO, Rebiotix

Panel Discussion: Probiotic Screening, Quality, Regulation and Testing

Challenges and solutions in probiotic screening

Strain designation, genus of species and efficacy

US regulation and GRAS notices

Quality assurance and scientific substantiation

CONFIRMED:

Chair: Susan Cho, President, Nutrasource, Inc.

Ravi Kumar, Scientist II, Novozymes Inc.

Buffy Stahl, Genomics and Microbiome Science Leader, DuPont Nutrition & Health

Seong Jae Yoo, Scientific Liaison, United States Pharmacopeia (USP)

5.30pm -5.45pm

Company Showcase: Human Microbiota: Proof of Concept to Production

General overview of live microbial production processes

Step by step process description with emphasis on process development

Considerations prior/during tech transfer focusing on specific requirements for pharma (GMP) production

CONFIRMED: Işil Tüzün Weber, Process Engineer Technical Operations Manufacturing, SynCo Bio Partners

Company Showcase: Developing Probiotics for the Oral Cavity - The Blis Story Blis Technologies (www.blis.co.nz) researches, manufactures and sells probiotics intended for the human oral cavity. Our company was founded on decades of research of Professor John Tagg who following his own encounter with strep throat as a child spent his career looking for natural ways to prevent this disease. The identification of a commensal oral bacteria called Streptococcus salivarius with unique anti-bacterial properties led to development of this strain into a novel probiotic for the oral cavity. Commercialisation of a new bacterial strain for a niche site presented many scientific, regulatory and technical challenges but also lead to the discovery of novel commercial opportunities for oral health conditions including halitosis, oral thrush dental caries and periodontal health. The simple application of a S. salivarius probiotic-containing lozenge can promote homeostasis in the oral cavity. This talk will highlight the journey taken by Blis and present both successes and challenges along the way.

CONFIRMED: John Hale, Research and Development Manager, BLIS Technologies, New Zealand

5.45pm -6.00pm

Company Showcase: In Vitro, In Silico and Study Design Strategies for Effective Metagenomics Trials

In this short talk, DNA Genotek will share two of our clients’ most commonly encountered challenges, and how we’ve solved them, namely:

How much noise / bias is acceptable in my samples? How will this amount of variation impact my analysis?

How can I maintain high participant engagement and ensure consistent phenotyping over the course of my longitudinal study?

CONFIRMED: Aaron Del Duca, Vice President, Technology, DNA Genotek

6.00pm -6.15pm

Company Showcase: Innovative Translational Gut Microbiome Technologies TNO and Triskelion’s long term experience with in vitro intestinal models (TIM) has been combined with microbiome models and technologies. Microbiome data obtained from human samples (from various organs) are analyzed by advanced bioinformatics approaches including machine learning. This combination of expertise and underlying research has resulted in unique in vitro models. These include the i-screen platform mimicking intestinal microbiota composition in a medium throughput format and the TIM2 model which is a more controlled in vitro model mimicking intestinal physiology. These models are increasingly used for pharmaceutical development including metabolite profiling. In combination with InTESTine, organ-on-a-chip and intestinal organoid technologies TNO and Triskelion can offer tailor made solutions to your specific research question related to microbiome. Applications of these technologies in the immunology (e.g. IBD), immuno oncology and infectious diseases are in progress.

CONFIRMED: Frank Schuren, Senior Scientist Microbiology, TNO

6.15pm Chairperson’s Closing Remarks & End of Day One

6.15pm-7.15pm

Drinks Reception [La Jolla Ballroom Salon E-H] If you would like to sponsor the drink’s reception please contact Gavin Hambrook at gavin@globalengage.co.uk

8.00am -8.40am

Networking Meetings and Coffee [La Jolla Ballroom Salon E-H]

8.40am -8.45am

Stream Chair: Bill Shannon, Founder & President, BioRankings LLC & Professor Emeritus of Biostatistics in Medicine, Washington University in St Louis, USA [La Jolla Ballroom Salon A-D]

8.45am -9.20am

Keynote Address: From the Human Microbiome Project to the Earth Microbiome Project The rapid decline in cost of sequencing technology together with advances in computational techniques has led to the possibility of integrating microbial knowledge across spatial and temporal scales. In this talk, I describe approaches developed for the Human Microbiome Project that allow us to map microbes from birth to death and across the body. I also describe how these human-associated microbial communities relate to those in the environment. Finally, I show how we can integrate chemical and microbial mapping to understand systems like the cystic fibrosis lung, and, ultimately, to take control of our own gut microbiology to improve our health.

CONFIRMED: Rob Knight, Professor of Pediatrics and Computer Science & Engineering, University of California, San Diego

9.20am-9.25am

Room Transition

Commercializing the Microbiome [La Jolla Ballroom Salon A-D] Stream Chair: Bill Shannon, Founder & President, BioRankings LLC & Professor Emeritus of Biostatistics

in Medicine, Washington University in St Louis, USA

Probiotics Congress [Soledad Ballroom] Stream Chair Moul Dey, Associate Professor, South Dakota State University

9.25am -9.50am

Sponsored Presentation: Title To Be Confirmed

CONFIRMED: Duncan Peyton, CEO, 4D pharma plc.

A Novel Multiplex PCR Method for Testing Multispecies Blends of Probiotics in Dietary Supplements. Beneficial bacteria are now offered in various forms of dietary supplements, with a trend towards formulations containing multiple species of probiotic strains. While identification of single microbial isolates is routine, typical methods such as 16S sequencing and classic microbiology are not flexible to commercial products of mixed microbial composition. We present a high resolution molecular test that can be used without culturing to quickly identify both species and subspecies of 20 commonly used probiotic strains in a single assay. Results of the application of this new testing method across a survey of commercially sourced products will also be discussed

CONFIRMED: Buffy Stahl, Genomics and Microbiome Science Leader, DuPont Nutrition & Health

9.50am -10.20am

Sponsored Presentation: Pioneering Development in the Gut Microbiome

Overview of RP-G28’s lactose intolerance indication development

Phase 2a microbiome data trends

Phase 2b/3 clinical trial status update

CONFIRMED: Michael Step, Chief Executive Officer, Ritter Pharmaceuticals

Sponsored Presentation: Monitoring Probiotics in the Human Gut Microbiome What happens when probiotics are introduced into complex microbial communities, how does the probiotics cope with the new environment and how will it impact the community? This is rarely understood in details. Here we introduce a suit of analysis concepts and tools that targets probiotics integration in the microbiome, incl. how the persistence of probiotics can be monitored in the gut microbiome, and how we can learn what facilitates persistence. Furthermore, we show how the microbiome response to new microorganisms can be monitored. Finally, we show how ultrahigh-resolution microbiomics can expand our microbiome analysis to cover previously un-sequenced microorganisms and how it can resolve the microbiome to strain level.

CONFIRMED: Henrik Bjørn Nielsen, Chief Scientific Officer, Clinical-Microbiomics

10.20am -10.50am

Sponsored Presentation: The Loss of a Major Commensal Microbe in Infants from Developed Countries Food allergies, atopy, asthma, Type I Diabetes and obesity are reaching epidemic proportions in the developed world. The acceleration in incidence of these conditions parallels a previously unrecognized disruption of the infant gut microbiome during the first six months of life, which may be the unintended consequence of C-Section deliveries, declines in exclusive human milk feeding, and increases in antibiotics use. The ideal microbiome of the neonate is one that is dominated by a single species that consumes the array of human milk oligosaccharides not otherwise utilized by the infant, and the majority of infants born in developed countries today may no longer harbor this key symbiont. We now have primary evidence demonstrating that this key symbiont, along with the unique colonic environment it creates, can be re-established in the gut of all infants.

CONFIRMED: David J. Kyle, CEO, Evolve Biosystems Inc.

Sponsored Presentation: Only the Fittest Survive: Heat Stable LactoSpore Probiotic

Learn how this shelf-stable probiotic, MTCC 5856, survives in high heat and can remain active even at room temperatures

Discover the possibilities of this probiotic in applications ranging from supplements to food categories, such as capsules, tablets, to bread and muffins

Come see the multitude of studies, ranging from IBS to MDD, that MTCC 5856 had an impact on

CONFIRMED: Anurag Pande, Vice President, Scientific Affairs, Sabinsa Corporation

Agenda: Day Two – Tuesday, 4 October 2016

10.50am -11.50am

Morning Refreshments [La Jolla Ballroom Salon E-H] Odd Numbered Poster Presentations & Scheduled One-to-One Meetings

Commercializing the Microbiome [La Jolla Ballroom Salon A-D]

Session Chair:

R&D Outside the Gut [ Irvine, Newport ]

Session Chair:

Probiotics Congress [Soledad Ballroom] Session Chair: Moul Dey, Associate Professor, South Dakota State

University

11.50am-12.20pm

Panel Discussion: Venture Capital and Microbiome Investment

What are companies looking for in a microbiome business investment?

Fundraising in microbiome

Venture Capital

Current market opportunities

Evaluating the funding climate

Perspective on building revenue models for the industry

CONFIRMED:

Chair: Malcolm Kendall, Co-Founder & CEO, Microbiome Insights, Inc.

Eric de la Fortelle, Venture Partner, Seventure Partners

Bernat Olle, Co-founder & Chief Operating Officer, Vedanta Biosciences, Inc. / Vice President, PureTech

COPD: The role of HIV and the Microbiome Next-generation sequencing techniques are now being used to understand changes in the lung microbiome in COPD. Studies have primarily focused on the bacterial communities in the lung microbiome. There has been little work examining the viral microbiome (virome) or the fungal microbiome (mycobiome), but these organisms likely play an important role in COPD and exacerbations. Viral and fungal communities may stimulate inflammation and lead to lung damage either directly or via impact on bacterial communities. The mycobiome has been examined in HIV-infected individuals with COPD. Analyses of bronchoalveolar lavage demonstrated that fungal communities were significantly different in HIV-infected individuals with COPD compared to HIV-infected individuals with normal lung function as well as different in those with HIV infection when compared to HIV-uninfected controls. The predominant change in the fungal communities was seen in differences in Pneumocystis jirovecii, a fungus that leads to opportunistic pneumonia (PCP) in HIV and has previously been linked to COPD in both the HIV-infected and HIV-uninfected population

CONFIRMED: Alison Morris, Professor of Medicine and Immunology, University of Pittsburgh

Shaping and Controlling the Microbiome with Human Milk Oligosaccharides Human milk oligosaccharides (HMO) are a family of structurally diverse complex sugars that are highly abundant in and unique to human milk. HMO alter host-microbe interactions on multiple levels and contribute to shaping the microbiome early in life. Originally, HMO were discovered as a prebiotic “bifidus factor” that serves as a metabolic substrate for desired bacteria and shapes an intestinal microbiota composition with health benefits for the breast-fed neonate. Today, HMO are known to be more than just “food for bugs”. An accumulating body of evidence suggests that HMO serve as soluble decoy receptors that prevent pathogen attachment to mucosal surfaces and lower the risk for viral, bacterial and protozoan parasite infections. HMO also directly impact bacterial growth to reduce the risk for infections. In addition, HMO modulate epithelial and immune cell responses to microbes. Our research program aims to characterize maternal factors that drive HMO composition, and discover HMO structure-activity relationships with potential for short- and long-term impact on maternal and infant health.

CONFIRMED Lars Bode, Associate Professor, University of California, San Diego

12.20pm-12.50pm

Understanding the Lung Microbiome and Host Mucosal Immune Response Interface Microaspiration is a common phenomenon in healthy subjects, its frequency is increased in several chronic inflammatory airway diseases. Aspiration-derived lung microbiota is associated with a distinct metabolic profile, demonstrating active microbial metabolism and challenging the prior preconception of sterility of the lower airways. Importantly, this enrichment of the lower airway microbiome with oral taxa is a major determinant of the inflammatory tone in the lower airway mucosa. The host immune phenotype associated with aspiration-derived lung microbiota is characterized by a Th-17 phenotype and a blunted alveolar macrophage TLR4 response. Targeting specific microbial metabolic pathways can impact host immune responses with important role on chronic airway inflammation

CONFIRMED: Leopoldo Segal, Assistant Professor, Department of Medicine, New York University School of Medicine

Sponsored Presentation: Human Milk Oligosaccharides are Powerful, Specific Modulators of the Adult Microbiota Human milk oligosaccharides (HMOs) powerfully shape the infant’s gut ecosystem, primarily by selectively stimulating the growth of specific bacteria; especially bifidobacteria. This selective stimulation creates a beneficial microbial community which is important for the infant’s development and health. These effects in infants have led to speculation that HMOs may be used more broadly to restore a healthy gut microbiota and health. However, these effects have been shown in infants only. We now show clinically that two HMOs are safe and well tolerated by healthy adults and are able to shape the adult microbiota and selectively stimulate the growth of specific bifidobacteria. We have also investigated the potential impact of this shaping on metabolites which are associated with human health.

CONFIRMED: Louise Vigsnæs, Preclinical Development Manager, Glycom A/S, Denmark

12.50pm -1.05pm

Company Showcase: Precision Microbiome Engineering in Agriculture and Beyond EpiBiome is working to curb the growing threat of multi-drug-resistant bacteria by eliminating the use of shared-class antibiotics in agriculture. Instead of antibiotics, EpiBiome deploys bacterial viruses known as phages, which are natural enemies of bacteria. These phages kill bacteria by giving them a lethal case of the flu. Phages have “Generally Recognized as Safe” (GRAS) status from the FDA for use on food intended for human consumption, and they pose no threat to humans. EpiBiome’s first product will address the bacteria that cause bovine mastitis, an infection of the udder tissue in dairy cows, which costs the global dairy industry $35 billion per year and is the #1 reason to give a cow antibiotics today. The company's strong expertise in bacterial profiling through next-generation sequencing will also be discussed.

CONFIRMED: Nick Conley, Chief Executive Officer, EpiBiome

Company Showcase: Microbiome Drug Development: How to Move Faster? Thanks to metagenomics and bioinformatics technologies, we can now recognize bacteria with a drug candidate potential. However, development process including strain identification, strain characterization, preclinical and clinical research phases have then to be performed, a time and money consuming procedure. Starting from a well-known bacteria with historical and documented use as Live Biotherapeutic Product to target new diseases is a good alternative to accelerate this process.

CONFIRMED: Maxence Desjonquères, Chief Executive Officer, Biose

No Presentation in this stream

1.05pm -1.35pm

Sponsored Presentation: Protecting the Gut Microbiome

Brief over of Intestinal Health and Importance of the Microbiome

Overview of SYN-004, Indication Aimed to Prevent Clostridium Difficile (C Diff) and Antibiotic Associated Diarrhea (AAD)

Overview of SYN-010, Indication Aimed to Treat Constipation Dominant Irritable Bowel Syndrome (IBS-C)

CONFIRMED: Isaac Bright, Vice President, Corporate Development, Synthetic Biologics, Inc.

Sponsored Presentation: Increasing Gut-barrier Function with Multispecies Probiotics Our gut epithelium is the largest bodily surface that separates our internal domain from the external world. The intestinal barrier prevents translocation of the trillions of bacteria and other compounds residing in the gut while allowing absorption of nutrients and water. The complex regulation of the intestinal barrier is determined by interactions between the host and the gut microbiota and can be disturbed by many factors. Problems with the gut barrier function have been associated with different intestinal (e.g. IBS, IBD) and extra-intestinal (e.g. metabolic, liver) diseases. The barrier function seems to play an important role even in the gut-brain axis, influencing de susceptibility to e.g. depression, migraine, ADHD and autism. Probiotics have been proven to prevent damaging of the epithelial barrier. In collaboration with research institutes, Winclove has developed a probiotic formulation that aims to restore the barrier integrity and reduce low-grade inflammation. Here we will present these developments, results of human trials as well as our expectations of further developments.

CONFIRMED: Elsbeth Pekelharing, Science Liaison, Winclove Probiotics

Panel Discussion: Exploring the Potential of Prebiotics

What is the potential of prebiotics?

Why are they exciting?

Where do we see it going in terms of therapeutics and a commercial standpoint?

Prebiotics v probiotics

CONFIRMED:

Chair: Keith Garleb, Director R&D Programs, Abbott Nutrition R&D

Michael Step, Chief Executive Officer, Ritter Pharmaceuticals

Brad Saville, Chief Scientific Officer/EVP & Founder, Prenexus Health

Bruce McConnell, Head of Business Development, Glycom A/S

1.35pm -2.35pm

Lunch [La Jolla Ballroom Salon E-H]

Gut Microbiome in Health & Disease [La Jolla Ballroom Salon A-D]

Afternoon Chair: Dario Gutierrez, Immuno-Biology Lead, Merck Research Laboratories

R&D Outside the Gut [ Irvine, Newport ] Afternoon Chair:

Probiotics in Animal Health [Soledad Ballroom]

Afternoon Chair:

2.35pm 3.00pm

The Microbiome Influences Homeostatic Control of Eukaryotic ABC Transporters at the Intestinal Mucosal Surface during Health and Disease The intestinal mucosa represents vast areas where host tissues are separated from the environment by a delicate but highly effective single layer of columnar epithelial cells, joined by tight junctions that selectively regulate movements of solutes and ions. This epithelial barrier functions normally in a state of tolerance to variations in dietary components and commensal bacteria, yet is poised to rapidly shift to an inflamed state where PMNs are recruited to protect the body from noxious materials and pathogenic bacteria. We have identified two sets of lipid-based signaling molecules that are released from the apical surface during periods of tolerance and inflammation that can control the recruitment of PMNs to the intestinal lumen. The role of the microbiome in intestinal function will be discussed in the context of the pathways that drive pro- and anti-inflammatory states in promoting injury or tissue healing.

CONFIRMED: Beth McCormick, Professor & Executive Director, Center for Microbiome Research, University of Massachusetts Medical School

Bacterial Transmission in Utero and Inflammatory Bowel Disease Bacterial transmission from the mother to the baby occurs in utero with the initial intestinal colonization playing a crucial role in the development of the mucosal immune system in early childhood and potentially predisposing to immune-mediated diseases later in life. The MECONIUM (Exploring MEChanisms Of disease traNsmission In Utero through the Microbiome) Study was designed to investigate the bacterial transmission from pregnant mothers with and without inflammatory bowel disease and compare the composition of their newborn’s and infant stool. The analyses, conducted in >80 families based on >700 samples including maternal stool, saliva, vaginal swab, placenta, amniotic membranes, and breast milk, as well as newborn umbilical cord blood, meconium, and serial infant stools, demonstrated a distinct signature of the disease in babies at birth and months thereafter.

CONFIRMED: Inga Peter, Associate Professor, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai

Identification of Metabolic Signatures in Canine IBD for Optimal Probiotic Selection Untargeted metabolomics analysis has yielded insights into the metabolomics changes occurring in dogs with IBD. These changes have been linked to depletion in specific species/strains within the microbiota. Using these bacterial species as probiotics may be useful for restoring the proper function of the gut microbiota.

CONFIRMED: Jan Suchodolski, Associate Professor, Department of Small Animal Clinical Sciences, Texas A&M University

3.00pm -3.25pm

Recombinant Bacteria for Treatment of Obesity-related Diseases Alterations in the gut microbiota have been implicated in the development of obesity and obesity-related chronic diseases such as atherosclerosis, establishing the gut microbiota as a therapeutic target. While many methods to alter the microbiota are possible, we have focused on incorporating bacteria that sustainably biosynthesize metabolites with therapeutic effects. To assess the potential of this approach, we engineered E. coli Nissle 1917 (EcN) to produce the leptogenic and anti-inflammatory lipid, N-acylphosphatidylethanolamine (NAPE). This presentation will discuss our findings in terms of wild-type mouse fed a high fat diet to induce metabolic syndrome and LDL receptor null mice fed a Western diet to induce non-alcoholic fatty liver disease and atherosclerosis. Additionally, the results of optimization studies for methods of administration will be discussed and their potential implications for eventual human trials.

CONFIRMED: Sean Davies, Associate Professor of Pharmacology, Vanderbilt University

Factors Influencing the Vaginal Microbiome and its Impact on Feminine Health and Wellness Numerous studies have demonstrated an imbalance in the vaginal/vulvar microbial communities can impact feminine health and comfort. Factors associated with vaginal microbiome imbalance including age, menstruation status, body mass index, and urinary incontinence. Development of an aberrant microbiome can be lead to issues such vaginal dryness and discomfort, increased risk of UTIs, yeast infections, and bacterial vaginosis. The dominance of Lactobacillus spp. have been associated with a healthy vaginal microbiome. To this end there can be a number of preventative countermeasures as well as treatments that can maintain or improve vaginal health through microbiome modulation. The presentation will give an overview of the microbial communities associated with both healthy and unhealthy female urogenital systems including the influence of age and body weight on the vaginal microbiome. A study demonstrating how the use of topically introduced probiotics can help re-balance the vaginal microbiome will be highlighted. Finally, the use of prebiotics to influence the vaginal microbiome and the future of pre- and probiotics in personal care products will be discussed.

CONFIRMED: Lindsay Peed, Lead Scientist Life Sciences, Microbiology, Kimberly-Clark

Animal Probiotics: Would One Size Fit All?

We identified potential probiotics associated with animal growth performance in beef cattle, pigs and chicken by analyzing their gut microbiomes using the Illumina MiSeq platform.

The potential probiotics identified from these animal species are different.

We propose the development of species-specific probiotics to promote farm animal growth performance.

CONFIRMED: Jiangchao Zhao, Assistant Professor, University of Arkansas

3.25pm -3.50pm

Validation Of The IntelliCap® System as a Tool to Study Changes in the Small Intestinal Microbiota in a Dietary Intervention Study The microbiota in the small intestine differs substantially from the fecal microbial community, but is at least as relevant for human health. Nevertheless, this ecosystem has barely been studied due to the invasive sampling procedures. The IntelliCap® system is an electronic medical device that has been adapted to aspirate liquid from its environment, and may thereby offer a minimally-invasive tool for sampling from the human small intestinal tract. This talk will explore whether the IntelliCap® system can be used as a tool to study the human small intestinal microbiota composition.

CONFIRMED: Harro Timmerman, Principal Scientist Microbiota in Health & Disease, NIZO Food Research BV, The Netherlands

The Effectiveness of Streptococcus salivarius against the Otopathogens of otitis media Streptococcus salivarius is an oral probiotic that is known and used commercially for its ability to inhibit the growth of oral pathogens. The potential ability of Streptococcus salivarius to inhibit the growth of Streptococcus pneumoniae, Nontypeable Haemophilus influenza and Moraxella catarrhalis will be investigated.

CONFIRMED: Robert Osgood, Associate Professor of Microbiology, Rochester Institute of Technology

A New Probiotic Strain Improving Gut Health in Young Pigs The swine industry is constantly working on implementing more sustainable production systems and is seeking new innovative feed additives to support this. Natural Bacillus bacteria with probiotic features have proven to have economically positive effect on health and performance. A new heat stable, probiotic strain for in-feed supplementation to young pigs will be presented. This comprises both in vitro as well as in vivo work. The new probiotic strain is a Bacillus subtilis subsp. subtilis which has proven to be able to improve piglet performance and health in connection with weaning - a stressful event, where piglets are moved from the sow and milk nutrition to a pen with new mates and industrial feed. This often leads to negative performance and reduced health of the piglets due to anorexia, gut malfunction and diarrhea.

CONFIRMED: Jens Noesgaard Jørgensen, Global Product Manager, Swine / Animal Health & Nutrition, Chr. Hansen

3.50pm -4.20pm

Afternoon Refreshments [La Jolla Ballroom Salon E-H] Even Numbered Poster Presentations

4.20pm -4.45pm

Microbiota and Mental Health: Gut Bacteria Influences Brain Structure and Behavior

Scientists have established a link between gut bacteria and anxiety-like behaviors in animal models and with emotional brain regions in healthy people.

Host genetics and environmental factors influence brain structure and behavior

Our results show that differences in relative abundance of clinically relevant commensals are also linked to brain structure and behavior

CONFIRMED: Jane Foster, Associate Professor, Department of Psychiatry & Behavioural Neurosciences, McMaster University, Canada

Targeted Modulation of Human Microbiome with Precision-guided Antimicrobial Peptides The lack of effective tools to modulate individual species within a complex microbial community poses a major barrier to studying human microbiome and its associated diseases. We developed novel precision guided antimicrobial peptides for the targeted removal of specific pathogen within complex microbiome communities. One of these compounds, C16G2, is currently at FDA phase II clinical trial for the targeted removal of human cariogenic Streptococcus mutans to treat and prevent tooth decay. The preliminary data showed its efficacy in modulating human oral microbiome into healthy conditions.

CONFIRMED: Brian Varnum, Chief Development Officer, C3 Jian Inc

Genomics-powered Screens for Identifying Best Fit Probiotics

Novozymes has a strain collection that contains thousands of bacterial strains

Bacterial strains are screened for safety, stability and performance to identify ones fit for probiotic use.

Presentation will be focused on our genomics and bioinformatics approaches to aid in screening and characterization of novel bacterial strains that have probiotic potential.

CONFIRMED: Ravi Kumar, Scientist II, Novozymes Inc.

4.45pm -5.10pm

Psychobiotics: Lactobacillus plantarum PS128 as an example A potential psychobiotic, Lactobacillus plantarum PS128, was identified and found to increase locomotor activity, normalize depression-like behaviors and altered brain neurotransmitter levels when orally administered to early life-stressed mice. In a rat model of IBS, PS128 administration significantly reduced the 5-HTP-induced visceral hypersensitivity, and alleviated the problem of alteration of the stress-related neuromodulator repertoire, including SP, BDNF, CGRP and NGF in dorsal root ganglia and the spinal cord, dopamine and serotonin in the prefrontal cortex, glucocorticoid receptor and mineralocorticoid receptor in the amygdala, and corticosterone in the serum. These results suggest that PS128 could be a potent alternative for neuropsychiatric disorder.

CONFIRMED: Ying-Chieh Tsai, Professor, National Yang Ming University, Taiwan

Dietary Raw Potato Starch Modulates the Butyrate-producing Microbiota and Host Immune Responses in Pigs Butyrate is critical for the maintenance of intestinal homeostasis. Inclusion of 5% raw potato starch (RPS) in weaning piglet diets significantly changes the intestinal bacterial community leading to an increase in butyrate and lactate concentrations in the proximal colon and cecum. Shifts in the microbial community were associated with concurrent changes in host immune responses suggesting increased tolerance of commensal microbes. These data suggest that RPS may be an effective prebiotic to promote gut health and mitigate early life intestinal complications.

CONFIRMED: Julian Trachsel, PhD Student, Iowa State University / USDA-ARS

5.10pm Conference Close

Venue

San Diego Marriott La Jolla

4240 La Jolla Village Drive

La Jolla, California 92037

United States

A discounted group rate will be available to all attendees. Details of how to book are available on registration. Space is limited and accommodation is available on a first come basis.

Title Principal Author(s) Affiliation

1 Oxalate metabolism results from redundant microbial networks

in the mammalian gut Aaron W. Miller Cleveland Clinic

2 Exposure to Bacterial Amyloid in the Gut enhances Alpha

Synuclein (AS) Misfolding and Neuroinflammation in the brain

Robert Friedland, Shu Chen, Madhavi Rane, Evelyne

Gozal, Shinying Jin, Rekha Jagadapillai, Andrew M.

Roberts, Ruolan Liu, Eliezer Masliah, Vilius Stribinskis

Univ. of Louisville

3 Impact of Short-Chain Galactooligosaccharides on the Gut

Microbiome of Lactose Intolerant Individuals

M. Andrea Azcarate-Peril1, Dennis Savaiano2,

Andrew Ritter3, and Todd R. Klaenhammer4

1Cell Biology and Physiology, and Microbiome Core

Facility, University of North Carolina, Chapel Hill 2Nutrition Sciences, Purdue University, W. Lafayette,

IN. 3Ritter Pharmaceuticals, Los Angeles, CA 4Food, Bioprocessing & Nutrition Sciences, North

Carolina State University, Raleigh, NC

4 Probiotic Standards from the United States Pharmacopeial

(USP) Convention

Seong-Jae Yoo†, Maria Monagas†, Kristie Laurvick‡,

Nandakurama Sarma†, and Gabriel Giancaspro†

Science Division-Dietary Supplements and Herbal

Medicines / Science Division-Food Standards ‡

†United States Pharmacopeia (USP)

5 MSPrebiotic® has a Bifidogenic impact on the gut microbiome

of elderly adults

Michelle J. Alfa, David Strang, Paramajit Tappia,

Morag Graham, Gary VanDomselaar, Jessica D.

Forbes, Vanessa Laminman, Nancy Olson, Pat

DeGagne, David Bray, Brenda-Lee Murray, Brenden

Dufault, Lisa Lix

St. Boniface Research Centre, 351 Tache Ave,

Winnipeg, MB, Canada

6 Determining the Impact of gums on the growth, viability and

beta galactosidase activity of probiotic microorganisms

Bernice D. Karlton-Senaye,1* Leonard L. Williams1,

Reza Tahergorabi,2 Valerie L. Giddings2 and Salam

A. Ibrahim2

North Carolina Agricultural and Technical State

University Center for Excellence in Post Harvest

Technologies, Kannapolis, NC, USA.

7 Metagenomic Investigation of Anti-obesity effects of laminarin

on diet-induced obese mice Son G. Nguyen, Jungman Kim, and Tatsuya Unno

Faculty of Biotechnology, College of Applied Life

Science, SARI, Jeju National University, Jeju, 690-756,

Korea

8 Lactobacillus fermentum ME-3: A Glutathione-Producing Strain

of Probiotic Bacteria Ross Pelton, Marc Freemont Essential Formulas Incorporated

9 AVVA Pharmaceuticals , human microecology is our calling Alexander Dikovskiy AVVA Pharmaceuticals Ltd

10 Kyung Eun Cha, Heejoon Myung Bacteriophage Bank of Korea, Hankuk University of

Foreign Studies, Yong-In, Gyung-Gi Do, Korea

11 Xylooligosaccharide supplementation alters gut bacteria in

both healthy and prediabetic adults

J Yang1, J Gu3, SM.Finegold1 , P Xavier2, D Heber1

and Z Li1

1Dr. Zhaoping Li, Center for Human Nutrition, David

Geffen School of Medicine, University of California,

Los Angeles, Los Angeles, CA, 2THT Prayon group, Lactoresearch, CHU and

University of Liège 3AIDP, Inc. City of Industry, CA

Posters

12 Development of a fecal microbiome test with a selected group

of commensal bacteria

Amy PeaceBrewer, Lihong Chen, Ashely Gibbon,

Mark Peucker, Teresa McBride, Darryl Landis

Amy PeaceBrewer, Lihong Chen, Ashely Gibbon,

Mark Peucker, Teresa McBride, Darryl Landis

13

Balancing the health of the inner and outer ecosystem: the role

of microorganisms in creating digestive and environmental

health in the face of global change

Ione Hunt von Herbing, K. Deming, T.-C. F. Pan and

M. S. Allen University of North Texas

14 Caries-Protective Effect of Arginine on Oral Microbial

Community

Melissa Agnello, Lujia Cen, Jeffrey McLean,

Xuesong He University of California, Los Angeles

15

Toxin-Antitoxin Stabilised Biosensors in Escherichia coli Nissle

1917 for the Detection of Dysbiotic Changes in the Intestinal

Microbiota

Tanel Ozdemir, Alex J. Fedorec and Chris P. Barnes Department of Cell and Developmental Biology,

University College London

16 Self-assembling cyclic peptides for modulating the gut

microbiome to treat atherosclerosis

Poshen B. Chen, Audrey S. Black, Purba Mukherjee,

Bhuvan Molparia, Yannan Zhao, Bruce E.

Maryanoff, Linda K. Curtiss, Ali Torkamani, Kristian

Andersen, Luke J. Leman, M. Reza Ghadiri

The Scripps Research Institute

17

Phage display - a powerful technology for identification of

eukaryote-interacting proteins from microbes and microbial

communities

Dragana Gagic, Filomena Ng, Wesley X. Wenn,

Milica Ciric, Graeme T. Attwood, Jasna Rakonjac

Massey University, Institute of Fundamental Sciences,

Palmerston North, New Zealand

18 A simple, low cost device enabling at-home gut microbiome

monitoring by consumers Alicia Scheffer-Wong, Jeff Rosner Floragraph

19 In situ production of prebiotics

Mikael Lenz Strube, Helle Christine Ravn, Hans-

Christian Ingerslev, Tim Kåre Jensen, Anne Strunge

Meyer, Mette Boye

20

Comparison of Methods for Evaluation of Hygiene Effects on

the Hand Microbiome: Standard Culture-Based versus Culture-

Independent Methods

C. Zapkaa,*, J. Leffb, J. Henleyb, J. Tittla,*, E. De

Nardoa, M. Butlerc, R. Griggsc, N. Fiererb, S. Edmonds-

Wilsona

aGOJO Industries, Inc., Akron, OH; bDepartment of

Ecology & Evolutionary Biology, Cooperative Institute

for Research in Environmental Sciences, University of

Colorado, Boulder, Colorado, cBioScience

Laboratories, Inc., Bozeman, MT

21

Tumor Necrosis Factor Receptor 2 regulates crosstalk between

CD8+ T cells and the gut microbiome to shape distinct

microbial milieu in colitis

Shivesh Punit, Philip E. Dubé, Cambrian Y. Liu,

Nandini Girish, M. Kay Washington, D. Brent Polk Children’s Hospital Los Angeles

22

Identification and functional characterisation of a novel

surface protein complex of probiotic bacterium Lactobacillus

rhamnosus

Wesley Wen, Dragana Gagic, Michael A. Collett,

Rachel C.Anderson and Jasna Rakonjac Massey University

23 Functional characterization of a rationally selected synbiotic

application in obese adults.

Janina A. Krumbeck, Heather E. Rasmussen, Ali

Keshavarzian, Krista Engen, Robert W. Hutkins, Jens

Walter

University of Nebraska-Lincoln

24 Microbiome Modulation of Neuronal Function in Autism

Spectrum Disorders George Mason University

Robert Brown, Patrick Gillevet, Chiara Manzini,

Jessica Wang

For further information please contact Steve Hambrook, Conference Director,

steve@globalengage.co.uk